Goldman Sachs and Morgan Stanley's strong earnings are giving analysts confidence that global investment banking is back in growth mode. When top-tier banks post blowout quarters, analysts typically upgrade competitors — and they're now pointing at Europe

Verdict: promising thesis, premature trigger — wait for ADX

The idea that UBS and Deutsche Bank ride the coattails of a Goldman-Morgan Stanley investment-banking revival has real fundamental teeth — UBS grew diluted EPS 55.3% to $2.36 and lifted ROE from 6.0% to 8.6% — but the trend-confirmation signals are not yet live. The 24-month UBS backtest returned 64.4% across 74 trades, yet its 35.1% win rate and 19.1% peak drawdown mean the strategy depends on outsized winners overwhelming frequent small losses, and those results rest on a single stock over two years. Deutsche Bank's 0.2% revenue contraction and bottom-quintile growth percentile (20.4th) undercut the idea's catch-up logic for the weaker name. Today neither stock triggers: ADX sits at 3.5 for UBS and 20.8 for DB against the required 25, and neither MACD line has crossed above its signal. No robust parameter setup was established, so the published thresholds stand as-is. This is a compelling setup to watch, not a trade to take today. **Conviction breakdown:** Thesis support scores well on UBS's earnings trajectory but is tempered by DB's flat revenue. Trade readiness is low — the critical ADX gate is far from met on both names. Risk quality is moderate given the tight 2.4% stop and roughly 2:1 reward-to-risk, though the drawdown path is punishing. Backtest evidence is decent in return terms but narrow in scope and hampered by a sub-35% win rate. Fundamentals trend is positive for UBS but mixed at best for DB.

Trade now

UBS closed at $52.42, sitting above its 50-day exponential moving average ($49.90) with the EMA 50 well above the EMA 200 ($44.92) — two of the four entry conditions are met. However, the ADX (14) reads just 3.5 against a required threshold above 25, a gap of roughly 21.5 points, meaning the strategy classifies current trend strength as far too weak to trigger a long. The MACD line has not yet crossed above its signal line either; it sits at 0.664 but the crossover event has not fired, leaving that condition flagged as near rather than met. In practical terms, wait means do nothing today — no position is warranted until ADX climbs above 25 and the MACD crossover prints on a daily close. The hard stop sits at a 2.4% loss from entry (exit rule at −2.43% unrealized), while the take-profit target is 4.9% (exit rule at +4.87% unrealized), giving an effective reward-to-risk ratio of roughly 2:1 on each triggered trade. This is a tight window; the backtest on UBS over 24 months produced 74 trades with a 35.1% win rate and a 64.4% cumulative return, but endured a 19.1% peak drawdown — so expect frequent small losses and position sizing accordingly (max 25% of equity per position). The signal exit (MACD crossing back below its signal line after 60 bars or RSI above 75) provides a secondary layer of defense beyond the fixed stops. For Deutsche Bank, the picture is similar: price at $35.51 is above the 50-day EMA ($34.50), and EMA 50 is above EMA 200 ($34.11), but ADX at 20.8 is 4.2 points short of the 25 threshold — closer than UBS but still not there. The MACD crossover on DB also remains untriggered. Both names require the same recipe: a tangible pick-up in trend strength and a MACD bullish crossover on the daily chart before the system would authorize an entry.

Why the bull case still has support

The idea's core argument — that blowout Goldman Sachs and Morgan Stanley quarters signal a global investment banking revival that lifts laggard European peers — finds genuine support in UBS's fundamental trajectory. Per the MarketWatch piece on July 22, 2026, analysts are explicitly pointing at European giants as the next beneficiaries, and UBS's earnings power backs that up. The bank reported diluted EPS of $2.36 for FY 2025, up 55.3% year-over-year, while net income reached $7.8 billion on $21.9 billion in operating cash flow. That is not a speculative turnaround story; it is a business generating real cash after absorbing Credit Suisse. The return-on-equity progression is where the thesis gets its teeth. UBS posted an ROE of 8.6% for FY 2025, sitting near the 46.8th percentile of Financials peers — hardly dominant, but a sharp recovery from the 6.0% posted in FY 2024. Zoom out further and…

Scores

• Conviction score breakdown: 47
• Thesis support: 62
• Trade readiness: 18
• Risk quality: 48
• Backtest evidence: 52
• Fundamentals trend: 55

Watch items

• UBS — ADX (14)
• UBS — MACD (12,26,9) crossover
• DB — ADX (14)
• DB — MACD (12,26,9) crossover
• UBS — RSI (14)
• DB — RSI (14)
• DB — Price above EMA (50)
• DB — MACD (12,26,9) crossed above MACD (12,26,9)
• DB — EMA (50) above EMA (200)
• DB — ADX (14) above 25